Bone Mineral Density Effects of Randomized Regimen and Nucleoside Reverse Transcriptase Inhibitor Selection from ACTG A5142

REFERENCES

• Rivas P, Gorgolas M, Garcia-Delgado R, Diaz-Curiel M, Goyenechea A, Fernandez-Guerrero ML. Evolution of bone mineral density in AIDS patients on treatment with zidovudine/lamivudine plus abacavir or lopinavir/ritonavir. HIV Med. 2008;9(2):89–95.
   PubMed Web of Science ®Google Scholar
• Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after anti-retroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009;51(5):554–561.
   PubMed Web of Science ®Google Scholar
• Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: A 3-year randomized trial. JAMA. 2004;292(2)191–201.
   Web of Science ®Google Scholar
• McComsey GA, Kitch D, Daar ES, et al. Bone mineral den-sity and fractures in antiretroviral-naive persons random-ized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: AIDS Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011 ;203 (12):1791–1801.
   PubMed Web of Science ®Google Scholar
• Haubrich RH, Riddler SA, DiRienzo AG, et al. Metabolic outcomes in a randomized trial of nucleoside, nonnucleo-side and protease inhibitor-sparing regimens for initial HIV treatment. AIDS. 2009;23(9):1109–1118.
   PubMed Web of Science ®Google Scholar
• Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358(20):2095–2106.
   PubMed Web of Science ®Google Scholar
• Duvivier C, Kolta S, Assoumou L, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibi-tor regimens in HIV-1 infected naive patients. AIDS (Lond). 2009;23(7):817–824.
   PubMed Web of Science ®Google Scholar
• Cassetti I, Madruga JV, Suleiman JM, et al. The safety and efficacy of tenofovir OF in combination with lamivu-dine and efavirenz through 6 years in antiretroviral-naive HIV-1-infected patients. HIV Clin Trials. 2007;8(3):164–172.
   PubMed Web of Science ®Google Scholar
• Yin MT, Shane E. Low bone-mineral density in patients with HIV: Pathogenesis and clinical significance. Curr Opin Endocrinol Diabetes. 2006;13(6):497–502.
   PubMedGoogle Scholar
• Jacobson DL, Spiegelman D, Knox TK, Wilson IB. Evolu-tion and predictors of change in total bone mineral density over time in HIV-infected men and women in the nutrition for healthy living study. J Acquir Immune Defic Syndr. 2008;49(3):298–308.
   PubMed Web of Science ®Google Scholar
• Pan G, Wu X, McKenna MA, Feng X, Nagy TR, McDonald JM. AZT enhances osteoclastogenesis and bone loss. AIDS Res Hum Retroviruses. 2004;20(6):608–620.
   PubMed Web of Science ®Google Scholar
• Zuccotti G, Vigano A, Gabiano C, et al. Antiretroviral therapy and bone mineral measurements in HIV-infected youths. Bone. 2010;46(6):1633–1638.
   PubMed Web of Science ®Google Scholar
• McComsey GA, LoRe V, 3rd, O’Riordan M, et al. Effect of reducing the dose of stavudine on body composition, bone density, and markers of mitochondrial toxicity in HIV-infected subjects: A randomized, controlled study. Clin Infect Dis. 2008;46(8)1290–1296.
   Web of Science ®Google Scholar
• van Vonderen MG, Lips P, van Agtmael MA, et al. First line zidovudine/lamivudine/lopinavir/ritonavir leads to greater bone loss compared to nevirapine/lopinavir/ritonavir. AIDS. 2009;23(11):1367–1376.
   PubMed Web of Science ®Google Scholar
• Jain RG, Lenhard JM. Select HIV protease inhibitors alter bone and fat metabolism ex vivo. J Biol Chem. 2002;277(22)1 9247–19250.
   PubMed Web of Science ®Google Scholar
• Fakruddin JM, Laurence J. HIV envelope gp120-mediated regulation of osteoclastogenesis via receptor activator of nuclear factor kappa B ligand (RANKL) secretion and its modulation by certain HIV protease inhibitors through interferon-gamma/RANKL cross-talk. J Biol Chem. 2003;278(48):48251–48258.
   PubMed Web of Science ®Google Scholar
• Grigsby IF, Pham L, Mansky LM, Gopalakrishnan R, Man-sky KC. Tenofovir-associated bone density loss. Ther Clin Risk Manag. 2010;6:41–47.
   PubMed Web of Science ®Google Scholar
• Looker AC, Melton LJ 3rd, Harris T, Borrud L, Shepherd J, McGowan J. Age, gender, and race/ethnic differences in total body and subregional bone density. Osteoporos Int. 2009;20(7)1141–1149.
   Web of Science ®Google Scholar
• Hui SL, Slemenda CW, Johnston CC, Appledorn CR. Effects of age and menopause on vertebral bone density. Bone Mineral. 1987;2(2):141–146.
   PubMedGoogle Scholar
• Nuti R, Martini G. Effects of age and menopause on bone density of entire skeleton in healthy and osteoporotic women. Osteoporos Int. 1993;3(2):59–65.
   PubMed Web of Science ®Google Scholar
• Dolan SE, Kanter JR, Grinspoon S. Longitudinal analysis of bone density in human immunodeficiency virus-infected women. J Clin Endocrinol Metabol. 2006;91(8):2938–2945.
   PubMed Web of Science ®Google Scholar
• Mondy K, Yarasheski K, Powderly WG, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003;36(4):482–490.
   PubMed Web of Science ®Google Scholar
• Dolan SE, Huang JS, Killilea KM, Sullivan MP, Aliabadi N, Grinspoon S. Reduced bone density in HIV-infected women. AIDS (Lond). 2004;18(3):475–483.
   PubMed Web of Science ®Google Scholar
• Fausto A, Bongiovanni M, Cicconi P, et al. Potential predic-tive factors of osteoporosis in HIV-positive subjects. Bone. 2006;38(6):893–897.
   PubMed Web of Science ®Google Scholar
• Grijsen ML, Vrouenraets SM, Steingrover R, et al. High prevalence of reduced bone mineral density in primary HIV-1-infected men. AIDS (Lond). 2010;24(14):2233–2238.
   PubMed Web of Science ®Google Scholar
• Bruera D, Luna N, David DO, Bergoglio LM, Zamudio J. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy. AIDS (Lond). 2003;17(13):1917–1923.
   PubMed Web of Science ®Google Scholar
• Brown TT, Qaqish RB. Antiretroviral therapy and the preva-lence of osteopenia and osteoporosis: A meta-analytic review. AIDS (Lond). 2006;20(17):2165–2174.
   PubMed Web of Science ®Google Scholar
• Yong MK, Elliott JH, Woolley IJ, Hoy JF. Low CD4 count is associated with an increased risk of fragility fracture in HIV-infected patients. J Acquir Immune Defic Syndr. 2011;57(3):205–210.
   PubMed Web of Science ®Google Scholar
• Thomas J, Doherty SM. HIV infection - a risk fac-tor for osteoporosis. J Acquir Immune Defic Syndr. 2003;33(3):281–291.
   PubMed Web of Science ®Google Scholar
• Cotter EJ, Lp HS, Powderly WG, Doran PP. Mechanism of HIV protein induced modulation of mesenchymal stem cell osteogenic differentiation. BMC Musculoskel Disord. 2008;9:33.
   PubMed Web of Science ®Google Scholar
• Gibellini D, De Crignis E, Ponti C, et al. HIV-1 triggers apoptosis in primary osteoblasts and HOBIT cells through TNFalpha activation. J Med Virol. 2008;80(9)1 507–1514.
   Web of Science ®Google Scholar
• National Osteoporosis Foundation. Clinician’s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008.
   Google Scholar
• Lundgren JD, Battegay M, Behrens G, et al. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. HIV Med. 2008;9(2):72–81.
   PubMed Web of Science ®Google Scholar
• Young B, Dao CN, Buchacz K, Baker R, Brooks JT. Increased rates of bone fracture among HIV-infected per-sons in the HIV Outpatient Study (HOPS) compared with the US general population, 2000–2006. Clin Infect Dis. 2011;52(8)1 061–1068.
   PubMed Web of Science ®Google Scholar
• McComsey GA, Tebas P, Shane E, et al. Bone disease in HIV infection: A practical review and recommendations for HIV care providers. Clin Infect Dis. 2010;51(8):937–946.
   PubMed Web of Science ®Google Scholar
• Franck H, Munz M. Total body and regional bone mineral densitometry (BMD) and soft tissue measurements: Cor-relations of BMD parameter to lumbar spine and hip. Calcif Tissue Int. 2000;67(2)111–115.
   Web of Science ®Google Scholar
• Boyanov M. Estimation of lumbar spine bone mineral density by dual-energy X-ray absorptiometry: Standard anteroposterior scans vs sub-regional analyses of whole-body scans. Br J Radiol. 2008;81(968):637–642.
   PubMed Web of Science ®Google Scholar
• Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS (Lond). 2012;26(7):825–831.
   PubMed Web of Science ®Google Scholar
• Huang JS, Wilkie SJ, Sullivan MP, Grinspoon S. Reduced bone density in androgen-deficient women with acquired immune deficiency syndrome wasting. J Clin Endocrinol Metabol. 2001;86(8):3533–3539.
   PubMed Web of Science ®Google Scholar
• Teichmann J, Lange U, Discher T, Lohmeyer J, Stracke H, Bretzel RG. Bone mineral density in human immunodefi-ciency virus-1 infected men with hypogonadism prior to highly-active-antiretroviral-therapy (HAART). Eur J Med Res. 2009;14(2):59–64.
   PubMed Web of Science ®Google Scholar
• Bang UC, Shakar SA, Hitz MF, et al. Deficiency of 25-hydroxyvitamin D in male HIV-positive patients: A descriptive cross-sectional study. Scand J Infect Dis. 2010;42(4):306–310.
   PubMed Web of Science ®Google Scholar
• Goicoechea M, Rieg G, Dube M, et al. Faster early viral decline with raltegravir (RAL) + lopinavir/ritonavir (LPV/r) vs. efavirenz (EFV)/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) in antiretroviral-naive patients: CCTG 589. Paper presented at: XVIII International AIDS Confer-ence; 2010; Vienna, Austria.
   Google Scholar
• Taiwo B, Zheng L, Gallien S, et al. Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS. 201125(17):2113–2122.
   Web of Science ®Google Scholar
• Burgos J, Crespo M, Falco V, et al. Dual therapy based on a ritonavir-boosted protease inhibitor as a novel salvage strategy for HIV-1-infected patients on a failing antiretro-viral regimen. J Antimicrob Chemother. 2012;67(6):1453–1458.
   PubMed Web of Science ®Google Scholar
• Patterson P, Magneres C, Sued O, et al. A phase 4, single-arm, open-label, pilot study of maraviroc, raltegravir and darunavir/r in HIV-1 adults with triple class failure: TER-CETO study. J Int AIDS. Soc. 2012 ;15(6):18268.
   Google Scholar
• Cenderello G, Penco G, Pontali E, Feasi M, Cassola G. Safety and efficacy of a raltegravir-based dual anti-retroviral therapy in clinical practice. J Int AIDS Soc. 2012;15(6):18353.
   Google Scholar
• Zolopa A, Ortiz R, Sax P, et al. Comparative study of tenofovir alafenamide vs. tenofovir disoproxil fumarate, each with elvitegravir, cobicistat, and emtricitabine, for HIV treatment. Paper presented at: 20th Conference on Retro-viruses and Opportunistic Infections; 2013; Atlanta, GA.
   Google Scholar